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S_nmary Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1
(0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over
60 mn without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and
retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a
median of 7.5 months (3-11 +). An additional 11 patients had stabilisation of disease. The patients received a
median of four cycles of docetaxel (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30
cycles; 14 cycles were delayed a mean of 3 days. Haematological toxicity consisted mainly of non-cumulative
neutropenia, with a median nadir count of 0.35 x 1091-1 (0.04-1.64) and eight episodes (5%0) of leucopenic
fever; non-haematological toxicities included alopecia, mild nausea and vomiting and allergic manifestations
such as skin rash and pruritus. There were no drug-related deaths. Our data indicate that docetaxel is an
active agent in advanced gastric cancer; further clinical investigations seem warranted.
Docetaxel is a novel semisynthetic taxoid obtained from
10-deaceryl baccatin III. a precursor extracted from the
needles of the European yew, Taxus baccata. It has demon-
strated activity against a variety ofpreclinical tumour models
(Bissery et al., 1991). In fact, at equitoxic doses, it proved to
be more active than paclitaxel (Taxol) against B16 murine
melanoma (Bissery et al., 1991).
Docetaxel works as an antimitotic agent, enhancing micro-
tubule assembly and inhibiting depolymerisation of tubulin,
resulting in the inability of cells to divide (Gueritte-Voegelein
et al., 1991; Ringel & Horwitz, 1991).
The dose-limiting toxicity of docetaxel in all schedules
tested in phase I clinical trials was neutropenia, but der-
matitis and stomatitis were also frequently observed
(Rousseau et al., 1991; Tomiak et al., 1991; Bruno et al.,
1992; Bissett et al., 1992; Pazdur et al., 1992; de Valeriola et
al., 1992; Bum's et al., 1993). When given as a 1 h infusion
every 3 weeks, dose-limiting oral mucositis did not occur.
The maximal tolerated dose (MTD) for a single dose
administration ranged between 90 and 115mgm-2. The
highest dose intensity was reached with the 1 h every 3 weeks
schedule compared with weekly administrations. Thus, this
schedule was selected for phase II clinical trials.
Carcinoma of the stomach remains one of the leading
causes of cancer-related deaths (Silverberg, 1985). Despite
maximal surgical efforts, results after resection of gastric
tumours are frequently dismal. A number of chemothera-
peutic agents are active in advanced, metastatic carcinoma of
the stomach (Kelsen, 1988). However, for most trials with
different combinations including the most active single
agents, response rates remain low, with median duration of
response ranging between 6 and 9 months and with median
survival of responders reaching less than 1 year (Macdonald
et al., 1980; Wils et al., 1986). The need for new active
compounds against this disease is obvious; gastric cancer was
therefore included in the panel of tumours selected for phase
II trials with docetaxel by the Early Clinical Tnrals Group
(ECTG).
We report here the results of this phase II clinical trial with
docetaxel given as a single agent to patients with advanced,
measurable, non-pretreated gastric cancer.
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Patients and methods
To be included in this tnral, patients had to have histo-
logically proven advanced gastric carcinoma with the
presence of at least one bidimensionally measurable indicator
lesion: a performance status (PS) of <2 (WHO scale). with
an adequate blood count (>4.0 WBCs, >2.0 granulocytes
and > 100 platelets x IO09-'), normal renal function with a
serum creatinine <140 imol 1-; if serum creatinine was
borderline (100-140;Lmoll-'), the creatinine clearance had
to be >60 ml min 1; transaminases were allowed to be up to
three times the upper limit of normal, without hyper-
bilirubinaemia (<1.25 times the upper limit of normal), in
the presence of liver metastases. Prior chemotherapy was not
allowed.
All patients underwent a detailed history and physical
examination. Baseline studies included a complete blood
count with differential, blood chemistry, urinalysis and an
ECG. Chest radiography, abdominal ultrasound or com-
puterised tomography and any other test to document fully
the extent of disease had to be performed within 2 weeks
prior to the first administration of docetaxel.
Ethical committee approval was granted and informed
consent according to institutional regulations was obtained
from all patients prior to treatment with docetaxel.
Docetaxel was given intravenously over 1 h at a dose of
100 mg m2 in 250 ml of a 5% dextrose solution or normal
saline once every 3 weeks. Premidication with antiemetics or
antiallergics was not used routinely; patients who developed
a hypersensitivity reaction to docetaxel were allowed
premedication with steroids and antihistamines in subsequent
cycles. The dose of docetaxel was not escalated even in the
absence of substantial toxicity.
The dose of docetaxel was reduced one level to 75 mg m-
for nadir granulocyte counts of <0.5 x 1091' lasting for
more than 7 days without fever or if fever > 38.5°C
developed during granulocytopenia; if necessary, docetaxel
was further reduced by an additional level, to 55mgm'.
Doses of docetaxel, if reduced, were not re-escalated. Subse-
quent treatments with docetaxel required peripheral blood
count recovery to at least 1.5 x 1091` granulocytes and
100 x 109 1-1 platelets, otherwise treatment was delayed for 1
week to allow for recovery.
If grade 2-3 skin toxicity occurred, doses of docetaxel
were reduced by 25%. Moreover, subsequent administrations
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were delayed up to 1 week, until recovery to < grade 1
toxicity.
The rate of infusion of docetaxel was decreased for mild
hypersensitivity reactions (HSRs), such as localised cutaneous
findings (flush, rash, pruritus, etc.). For more pronounced
symptoms, including generalised pruritus, flushing and rash,
dyspnoea and hypotension with systolic blood pressure
>80 mmHg, the docetaxel infusion was stopped and intra-
venous antihistamines and steroids were administered. The
infusion of docetaxel was continued after symptom
recovery.
In the event of a severe HSR, with bronchospasm, general-
ised urticaria, angio-oedema or hypotension below 80 mmHg
systolic, the docetaxel infusion was stopped and antihista-
mines and steroids were given i.v. Docetaxel infusion was
restarted within 72 h using premedication with antihistamines
and steroids, and this was then repeated with each subse-
quent cycle.
A partial remission was defined as a decrease of at least
50% in the sum of the products of the largest perpendicular
diameters of measurable lesions as determined in two obser-
vations, not less than 4 weeks apart, in the absence of an
increase in any of the known lesions or the appearance of a
new one.
Stabilisation of disease required less than 50% decrease or
less than 25% increase in the sum of the product of the
longest perpendicular diameters of all measurable lesions
without the appearance of a new lesion.
Patients had to receive at least two courses of docetaxel to
be evaluable for response; the anti-tumour effect of docetaxel
was assessed every two cycles. Response duration and sur-
vival were calculated from the onset of docetaxel therapy.
Resdts
A total of 42 patients with advanced gastric cancer were
entered into the study. Of the 42 patients, five were con-
sidered ineligible: two lacked clearly measurable disease, one
had his baseline work-up performed more than 3 weeks prior
to the onset of docetaxel chemotherapy, one patient had an
elevated bilirubin and the fifth patient did not meet the
eligibility criteria because of lack of informed consent and
therefore did not receive treatment
The main characteristics of the 37 eligible patients are
depicted in Table I. The median PS was 1, and the most
common metastatic sites were the liver and the retro-
peritoneum. In 18 patients (49%), the primary tumour had
not been surgically removed; in the remaining patients, the
interval between surgery and docetaxel chemotherapy ranged
from 3 weeks to 60 months (median 8 months).
None of the patients had received chemotherapy prior to
docetaxel.
Toxicity
Overall, 156 cycles of docetaxel were delivered to these
patients for a median of four cycles per patient (range 1-8).
Dose reduction was necessary in 30 cycles (19%) given to
eight patients, mainly because of myelosuppression or scin
toxicity; doses were decreased to 75mgm-2 in 16 courses
and to 55 mg m 2 in 14. The full dose of 100 mg m 2 could
be given as originally planned in the remaining 126 courses
(81%). Delay in the administration of docetaxel was neces-
sary in 14 cycles (9%), for a median of 3 days and never
more than 7 days.
Haematological and non-haematological toxicities are sum-
marised in Tables II and III. The most common haemato-
logical side-effect was neutropenia, with nadir counts occurr-
ing most frequently on day 7 of each cycle (5-14 days).
Recovery was observed by the time of the next blood count,
i.e. within I week of the nadir count. Thus, while 26 patients
(70%) developed grade III-IV leucopenia and 35 patients
(95%) had grade III-IV neutropenia, leucopenic fever
developed in only 8 of the 156 cycles (5%); all patients
recovered uneventfully with parenteral antibiotics. Neutro-
penia was not cumulative and thrombocytopenia did not
occur.
The most frequently observed non-haematological side-
effects were: alopecia, mild to moderate nausea and vomiting,
diarrhoea, asthenia and fatigue, myalgias and arthralgias.
Mild sensory neurological toxicity, characterised by paraes-
thesiae, occurred in nine of the patients.
Mild to moderate dermatological toxicity was observed in
21 patients, characterised mainly by skin desquamation and
dryness, pruritus and a maculopapular rash, sometimes
generalised. Nail changes, occasionally marked, were also
seen.
HSRs, mild to moderate, characterised by flushing, skin
rash and sometimes shortness of breath, were described in
nine patients. This occurred mostly shortly after the onset of
the first docetaxel infusion; permanent discontinuation of
docetaxel owing to an HSR was not necessary in any
patient.
Tabe I Patient characteristics
No. of registered patients 42
Number ofeligible patients 37
Median age (range) (years) 59 (37-72)
Male/female 27/10
PS, median (range) 1 (0-2)
Sites of disease
Retroperitoneal nodes 16 (43%)
Primary tumour 13 (35%)
Liver 12 (32%)
Intra-axbdominal/pelvic mass 3 (8%)
Table H Haematological toxicity
Median nadir (range)
x la9 1-O First cyke Last cycle Overall
WBCs 2.1 (03-4.9) 2.1 (0.3-5.7) 1.8 (0.3-4.0)
Granulocytes 0.47 (0.04-3.15) 0.71 (0.04-2.3) 0.35 (0.04-1.64)
Platelets 271 (205-474) 278 (215-613) 250 (176-401)
Hb, g/. 10.1 (5.2-13.9) 10.1 (5.8-14.2) 8.9 (5.2-12.6)
Day nadir median (ne) 7 (5-14)
Episodes of copenic fever/patients 8/7
B g des 0
Table m Non-hacmatological toxicity (NCI-CTC gradingr
Grade
I II III I}
k-effect ~~~(%) (°/) (%) (°A
Nausea
Vomiting
Diarrhoea
Fatigue, asthenia
Dermatological
Alopecia
Stomatitis
Paraesthesia
ADergy
Headache
Constipation
Myalgia
Loc pain
Unpeasant taste
Cardiac dysrhythmia
Perip aoedema/weight n
Fever
"Worst grade per patient.
27
19
30
24
19
16
27
22
11
5
8
11
0
5
0
8
3
22
16
13
30
32
73
5
3
11
3
5
8
11
3
0
13
13
3
3
0
16
3
0
5
0
3
0
3
0
0
0
3
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
Table IV Antitumour activity in 37 eligible patients
Duration ofresponse (months)
No. % Median (range)
Partial remission 8 22 7.5 (3-11+)
No change 11 30 4 (3-8)
Progression 14 38
Non-evaluable 4 10
Total 37 100
V
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Table V Responders
No. of Taxotere Percent decrease in Duration of Survival
No. Age Sex PS cycles to PR Indicator lesion tumour measurement PR (months) (months)
1 66 M 0 2 Retroperitoneal lymph 61 4 6
nodes
2 38 M 2 2 Mediastinal, presternal 94 8 10
and supraclavicular
masses
3 44 M 2 4 Retroperitoneal lymph 55 8 17
nodes
4 72 F 2 2 Primary tumour 84 3 3
5 68 M 2 2 Skin nodules 96 5 7
6 67 M 0 2 Liver 100 11+ 11+
7 61 M 1 2 Abdominal wall mass 100I 7+ 7+
8 71 M 0 4 Retroperitoneal lymph 90 10 11
nodes
'Non-measurable disease, not completely disappeared.
Weight gain of > 2 kg was recorded in 8 of the 37
patients, all of whom had received four cycles or more of
docetaxel. This was due to fluid retention, which resulted in
peripheral oedema and sometimes pleural effusions (tran-
sudates). The median weight gain in these eight patients was
6.2 kg (range 2-13 kg).
Three cardiac events (two supraventricular arrhythmias in
the form of paroxysmal atrial tachycardia and atrial fibrilla-
tion and one episode of coronary ischaemia) occurred in two
patients while on docetaxel chemotherapy. The supraventri-
cular arrhythmias occurred on day 4 of the first cycle and on
day 8 of the second cycle of docetaxel, and subsided in both
patients with conventional therapy. Both patients were
uneventfully rechallenged with docetaxel.
Anti-tumour activity
Eight patients achieved a partial remission; seven of these
eight responses have been externally and independently
reviewed and confirmed. The median duration of response
was 7.5 months (range, 3 to 11 + months) (Table IV). Re-
sponses occurred in a variety of metastatic sites (Table V)
including the liver (one patient), retroperitoneum (three
patients), soft-tissue masses in the abdominal wall (one
patient) and in the neck and mediastinum (one patient). One
patient had multiple cutaneous nodules, and in another
patient the primary tumour site responded to docetaxel.
None of the remaining patients who had not undergone
gastrectomy responded at the primary site.
Eleven patients had stabilisation of disease for a median of
4 months (range 3-8 months). Disease progression occurred
in 14 patients, including three patients in whom progression
was documented during the first 6 weeks ofdocetaxel chemo-
therapy ('early progression'). Response could not be assessed
in the remaining four patients: one refused further docetaxel
chemotherapy following the first administration, one patient
died suddenly at home of unknown causes on day 14 of the
first cycle, one proved to have no measurable lesion upon
review and the fourth patient refused further treatment and
evaluation after two courses.
The partial remission rate calculated for all 42 patients
registered into the trial is 19%; it is 22% for the 37 eligible
patients and 24% for the 33 evaluable patients.
Responses to docetaxel did not correlate with initial PS,
age, metastatic sites, degree of myelosupression or the
presence of an HSR to docetaxel. Seven of the eight re-
sponders were male. Six of 11 female patients, all PS 0-1,
had stabilisation of disease while on docetaxel. Responses
occurred more frequently in patients who underwent resec-
tion of the primary tumour than in those who did not: 7/19
(37%) vs 1/18 (5%) (P = 0.06).
The results of this clinical trial indicate that docetaxel is an
active drug against gastric cancer. In fact, the response rate
achieved with docetaxel is similar to the single-agent activity
observed with the most active conventional drugs in use in
this disease, such as 5-fluorouracil, doxorubicin, cisplatin and
mitomycin C. Responses were usually observed after two
courses of docetaxel and occurred in a variety of metastatic
sites, including the liver, with a median duration of 7.5
months. Response at the primary tumour site was observed
in only one patient. Patients who had undergone a gastrec-
tomy with resection of the primary tumour had a higher
response rate than patients whose tumour was not removed.
Patient in this last category probably had more advanced
disease with a larger tumour burden.
While most cycles of docetaxel were given according to the
originally planned dose and schedule, a wide variety of side-
effects were recorded. Neutropenia represented the major
toxicity for most patients; nevertheless, there were only eight
episodes (5%) of leucopenic fever requiring hospital admis-
sion, reflecting the prompt recovery of the leucocyte
count.
The non-haematological side-effects included dermato-
logical reactions as well as mild to moderate HSRs, which
were subsequently controlled with antiallergic premedication
and never led to the discontinuation of docetaxel. Some
patients complained of fatigue and myalgias while on treat-
ment with docetaxel. Most troublesome, however, was the
development of a fluid retention syndrome, observed mainly
in patients receiving four or more cycles of docetaxel and
characterised by weight gain, peripheral oedema and pleural
effusion. This syndrome has also been observed in other
phase II trials with docetaxel carried out by the ECTG, a
detailed description of which is reported elsewhere (Wanders
et al., 1993); preliminary data suggest that corticosteroids
might benefit these patients to some extent.
There has been a growing disappointment with the use of
drug combinations such as FAM (Biran et al., 1989) or, more
recently, EAP (Taal et al., 1990) in the treatment of
advanced gastric cancer, making the need for novel, active
and, hopefully, less toxic combinations urgent. Recently, the
use of paclitaxel in 20 patients with advanced adenocar-
cinomas of the upper gastrointestinal tract resulted in only
one partial remission (Einzig et al., 1993). In contrast, the
present study does inidcate definite activity for docetaxel, and
the difference may partly be explained by the extent of prior
chemotherapy.
Further clinical investigations with docetaxel in patients
with carcinoma of the stomach are certainly warranted based
on the experience reported here, including the use of
docetaxel in combination with other active drugs in this
disease, such as the anthracyclines, 5-fluorouracil and others.
Other possible venues for investigation include the routine
use of premedication to circumvent HSRs and the fluid
retention syndrome, and the concomitant administration of
granulocyte colony-stimulating factor (G-CSF).
These investigations shall define the precise role of
docetaxel in the overall treatment of gastric cancer.DOCETAXEL IN ADVANCED GASTRIC CANCER 383
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